EUVIMEDEUVIMED entdecken
Crossref

Frontline Management of Nodal Peripheral T-Cell Lymphomas

Henry S Ngu, Kerry J Savage iD

American Society of Clinical Oncology Educational Book · 2023

DOI: 10.1200/edbk_390334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Society of Clinical Oncology Educational Book, 2023. Verfasst von Henry S Ngu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Lymphoid Cancer BC Cancer, Division of Medical Oncology, BC Cancer and University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peripheral T-cell lymphomas (PTCLs) represent only 10%-15% of all non-Hodgkin lymphoma but encompass a diverse group of diseases with over 30 different subtypes. As a result of both disease heterogeneity and rarity, therapeutic progress of PTCLs has lagged behind B-cell lymphomas with very few randomized controlled studies to guide management. The most common subtypes are the so-called nodal PTCLs: PTCL-not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), and nodal T follicular helper cell lymphoma (TFHL) lymphoma, the latter of which includes angioimmunoblastic T-cell lymphoma. Anthracycline-based primary chemotherapy is still the mainstay of treatment for these common PTCL subtypes, but in recent years, we have moved into an era where more personalized therapy can be applied in some settings. Cyclophosphamide, doxorubicin, prednisone, and brentuximab vedotin CHP-BV is the first therapy in PTCL to show an overall survival benefit and represents a new standard for ALCL; however, there is less therapeutic certainty in other CD30-positive PTCLs. Recurrent mutations of epigenetic modifier genes typify TFHLs lymphomas, and collective studies demonstrate a heightened sensitivity to epigenetic therapies, leading to trials integrating these agents in the frontline setting. Molecular studies of PTCL-NOS have defined at least two subtypes, GATA3 and TBX21, the former having a poorer prognosis, but how this guides therapeutics remains unknown. Outside of ALCL, there is a growing debate as to whether trials should focus on adding a novel agent to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or whether combination novel therapies should be explored in the frontline therapy setting. Finally, the role of consolidative autologous stem-cell transplant in first remission remains an area of active debate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralHumansPrednisoneBrentuximab VedotinCyclophosphamideDoxorubicinAntineoplastic Combined Chemotherapy Protocols

Substanzen

PrednisoneBrentuximab VedotinCyclophosphamideDoxorubicin

Autor:innen und Institutionen

  • Centre for Lymphoid Cancer BC Cancer, Division of Medical Oncology, BC Cancer and University of British Columbia, Vancouver, BC, Canada.

ORCID-Profile: Kerry J Savage

Zitieren

APA

Ngu, H. S., & Savage, K. J. (2023). Frontline Management of Nodal Peripheral T-Cell Lymphomas. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_390334

Vancouver

Ngu HS, Savage KJ. Frontline Management of Nodal Peripheral T-Cell Lymphomas. American Society of Clinical Oncology Educational Book. 2023. doi:10.1200/edbk_390334

BibTeX
@article{Ngu2023,
  author = {Ngu, Henry S and Savage, Kerry J},
  title = {Frontline Management of Nodal Peripheral T-Cell Lymphomas},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2023},
  doi = {10.1200/edbk_390334}
}
Kostenlos starten →